Money Morning mentions RHT in latest white paper...

Money Morning mentions RHT in latest white paper

https://www.moneymorning.com.au/wp-...y-morning-small-cap-stocks-set-to-explode.pdf

"Artificial intelligence and the healthcare industry are about to collide together in a big way. And potentially make some early investors a fortune. One stock on the ASX you could look into here is Resonance Health Ltd [ASX:RHT]. Resonance’s main product is called FerriScan® which provides an accurate measurement of liver iron concentration by using AI-sorted (FerriSmart® data from MRI scans. Their other product is called HepaFat-Scan® which looks at fat in liver tissue. Crucially, both have regulatory clearance in the USA, Europe, and Australia. Their products which use artificial intelligence (AI) have been clinically shown to be superior to the comparably slower, complicated, and expensive traditional liver biopsy. Knowing how much iron is in the liver is relevant to the treatment of sickle cell anaemia, people who receive a lot of blood transfusions as well as people with heart conditions. The bottom line is this: why spend all that time and money cutting people open when you can just run them through the MRI scanner and have AI sort out the data? That’s what Resonance’s state of the art products do. The WHO estimates that 5.2% of the world have haemoglobin disorders (sickle cell and thalassemia), so that’s a massive addressable market for Resonance. Likewise, HepaFat-Scan® has implications for other liver problems, and perhaps most importantly diabetes which is a huge trend in health. With the company making inroad into the US, this company could be poised to take the next step in 2020. AI plus healthcare is the future…"